Public Comment Proposal

Enhance Transplant Program
Performance Monitoring System

OPTN Membership and Professional Standards Committee

Prepared by: Sharon Shepherd
UNOS Member Quality

Contents

Executive Summary 2
Background 3
Purpose 4
Overview of Proposal 4
NOTA and Final Rule Analysis 30
Implementation Considerations 31
Post-implementation Monitoring 33
Conclusion 35
Bylaws Language 37
Appendix A 42
Enhance Transplant Program Performance Monitoring System

Affected Bylaws: Appendix D, D.12.A. Transplant Program Performance
Appendix M, M.3 Medical Peer Review
Appendix M, M.6 Peer Visits
Appendix M, M.9 Informal Discussions
Appendix M, M.15 Costs and Expenses
Appendix N: Definitions

Sponsoring Committee: Membership and Professional Standards

Public Comment Period: August 3, 2021 – September 30, 2021

Executive Summary

The Membership and Professional Standards Committee (MPSC) conducts transplant program performance reviews under the authority of the Organ Procurement and Transplantation Network (OPTN) Final Rule §121.10 (b)(1)(iii) that requires that the OPTN establish plans and procedures for conducting ongoing and periodic reviews and evaluations of transplant hospitals for compliance with the Final Rule and OPTN bylaws and policies. This responsibility is further defined by the OPTN contract with the Health Resources & Services Administration (HRSA), which requires the contractor to “monitor OPTN member performance, including threats to patient health and public safety, maintain and develop efforts to improve OPTN member performance, and impose sanctions when warranted.”

Currently, the MPSC uses a single metric, one-year post-transplant graft and patient survival, for identifying underperforming transplant programs. The MPSC recognizes the need to incorporate metrics that evaluate multiple phases of transplant care, to create a more holistic approach to evaluation of transplant program performance. The MPSC proposal seeks to modify the OPTN Bylaws Appendix D.12.A. Transplant Program Performance. Specifically, the proposal identifies new metrics, which evaluate both pre-and post-transplant aspects of patient care that the MPSC will use to assess transplant program performance to ensure these programs are performing safely. The proposal also establishes which transplant programs must participate in performance reviews by setting specific boundaries for each metric. The proposal re-organizes and clarifies, but does not substantively change, transplant program obligations to participate in the performance review process. In addition, the proposal includes a new section in Appendix M: Review and Actions that codifies the current peer review process. Other administrative changes have been made to Appendix M: Reviews and Actions and Appendix N: Definitions. The MPSC asserts that this proposal improves upon the current performance evaluation system using reliable, available metrics that measure multiple aspects of transplant program patient care to create a better, more holistic transplant program performance monitoring system.
Background

Criteria for review of transplant program performance has been included in the bylaws since as early as 1987. Since that time, programs have been evaluated based on their one-year patient and graft survival rates. The initial criteria identified any transplant program whose survival rates fell into the bottom five percent of transplant programs. Over time, the criteria have been adjusted to incorporate advances in statistical analysis. For example, in 1992, criteria were updated to incorporate risk-adjustment, meaning individual donor and recipient characteristics are considered when calculating a program’s expected survival rate and further refined in 2003. In 2014, criteria were updated to incorporate the Bayesian methodology. The Bayesian methodology and changes to the thresholds improved the ability of the MPSC to identify potentially underperforming medium and small volume programs. However, other attempts to modify the transplant program performance requirements stalled. In 2014, the MPSC sponsored a public comment proposal to incorporate a composite pre-transplant metric in the review process, but the MPSC did not submit to the Board of Directors for approval due to concerns raised during public comment. In 2016, the MPSC sponsored a public comment proposal to shift to a four-tier review method that would continue to exclusively utilize the one-year patient and graft survival metric, but this likewise was not pursued further due to concerns raised during public comment.

One common critique of the current system is its reliance on a single, post-transplant survival metric. Many in the community have questioned whether this singular metric sufficiently assesses the various aspects of program performance. Community members have also suggested that the overemphasis on post-transplant outcomes may result in risk-aversion and decreased transplant volumes.

In 2018, the OPTN Board President established the OPTN Ad Hoc Systems Performance Committee (SPC), and charged the SPC with considering metrics and elements that could be universally accepted as performance standards, not only for transplant programs, but also for organ procurement organizations (OPOs) and the transplant system as a whole. The SPC also considered ways the OPTN could support the system performance. In its report to the OPTN Board of Directors in June 2019, the SPC provided recommendations across four areas, including performance monitoring enhancements. The SPC stated a holistic approach to the evaluation of transplant hospital and OPO performance would be beneficial and suggested developing a balanced scorecard approach that incorporated multiple metrics. Although the SPC identified metrics for possible inclusion in a scorecard, the SPC acknowledged the need for more input and work to identify and define the appropriate metrics for scorecards. After the SPC report to the Board, the MPSC was asked to continue work on this topic.

---

1 United Network for Organ Sharing (UNOS) Bylaws, Appendix B (3) Survival Rates, effective August 10, 1987
7 https://optn.transplant.hrsa.gov/members/committees/ad-hoc-systems-performance-committee/

Public Comment Proposal
Purpose

In determining the specific goals of the project, the MPSC reviewed the OPTN’s responsibilities regarding member reviews and evaluations under the OPTN Final Rule, the OPTN contract, and the MPSC charge\(^9\). The MPSC also considered the mission, vision, and goals within the 2018-2021 OPTN Strategic Plan\(^{10}\); and themes and recommendations described in the SPC report to the OPTN Board of Directors.

During its discussions, the MPSC acknowledged a few key goals that would shape the project. First, the MPSC understood that any proposal must be within the OPTN and MPSC’s authority. There are many possible approaches to performance monitoring and metrics to consider; however, the MPSC must focus on areas clearly within the stated authority, which is addressed in subsequent sections of this proposal. Second, the MPSC acknowledged it has a fiduciary responsibility to monitor member performance to identify potential patient safety issues. At the same time, the MPSC strives to support and collaborate with transplant programs to address performance improvement opportunities. The MPSC also wanted to develop a performance review system that would provide maximum support for the OPTN Strategic Plan, specifically increasing the number of transplants, promoting equitable access to transplantation and fostering innovation. The MPSC agreed that the proposal should develop a holistic review of member performance throughout all phases of transplantation. Finally, the MPSC acknowledged the need to improve the current performance review process, and committed to completing a proposal in a timely fashion.

The MPSC also recognizes that this proposal is the first step in moving beyond a singular focus on one-year post-transplant outcomes to evaluate transplant program performance. The Committee established a framework while developing this proposal that will be used to continue to consider improvements to the performance review process through the evaluation of the effectiveness of this proposal as well as the consideration of other measures that may become available in the future to continue to drive better transplant program performance.

Overview of Proposal

The MPSC proposal establishes new pre- and post-transplant metrics and sets boundaries for each metric to identify transplant programs for MPSC performance review. Under the proposal, a transplant program will enter review if it meets any of the criteria set for each metric. Additionally, there are separate criteria for adult and pediatric transplants. The proposal re-organizes and clarifies, but does not substantively change, transplant program obligations to participate in the performance review process. In addition, the proposal includes a new section in Appendix M, Review and Actions that codifies the current peer review process. Other administrative changes have been made to Appendix M, Review and Actions to ensure consistency with the new peer visit section and Appendix N: Definitions to delete definitions for two defunct MPSC standing subcommittees and update the definition for the SRTR.

To develop a proposal that met the key goals of the project, the MPSC evaluated the purpose of MPSC performance monitoring of transplant programs, the elements of the transplant process, what metrics reliably evaluate key aspects of transplant program patient care, and appropriate boundaries for each metric that accurately identify transplant programs that may pose a potential risk to patient health or public safety while reducing the number of false positive identifications.

\(^9\) https://optn.transplant.hrsa.gov/members/committees/membership-and-professional-standards-committee/
\(^{10}\) https://optn.transplant.hrsa.gov/media/2392/executive_publiccomment_strategicplan_20180122.pdf
Initially, the MPSC determined the elements of the transplant process that are impacted by transplant programs and which elements should be measured by the MPSC for performance monitoring. The MPSC discussed the continuum of care transplant programs provide to patients and identified potential measures to assess a program’s performance in each area, which combined can provide a more holistic review of transplant program performance. The MPSC sought to identify metrics that measured independent and distinct phases of transplant care, rather than relying on a single one-year post-transplant survival metric. The MPSC wanted to avoid utilizing overlapping metrics, which the MPSC felt may result in an inappropriate increase in programs being identified for review. The MPSC also reviewed data on the correlation between various metrics to ensure that the Committee selected at least one metric for each phase of care, and that the metric chosen independently measures a program’s performance on that phase.

The MPSC ultimately identified two main areas along the continuum of care: waitlist management (pre-transplant care) and post-transplant outcomes. Within those areas, the MPSC further identified specific phases to evaluate. For waitlist management, the MPSC identified waiting list patient care and organ offer acceptance practices. For the post-transplant outcomes aspect of patient care, the MPSC identified peri-operative care and post-operative patient care. In its collective experience, the committee believes that patient outcomes pre-transplant are as important as post-transplant outcomes in the assessment of transplant program performance and quality as research has shown that post-transplant outcomes are better than outcomes for patients that remain on the waiting list.11

Within the context of the above framework, the MPSC considered the measures the SPC recommended for consideration, identified in Table 1 below:

<table>
<thead>
<tr>
<th>Table 1: Transplant Program Possible Metrics Suggested by SPC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-Transplant</strong></td>
</tr>
<tr>
<td>Intent-to-treat analysis</td>
</tr>
<tr>
<td>Offer acceptance rate (risk-stratified, DRI, KDPI, etc.)</td>
</tr>
<tr>
<td>Active vs. inactive status</td>
</tr>
<tr>
<td>Survival from listing</td>
</tr>
<tr>
<td>Waitlist mortality rate</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

The MPSC also discussed additional elements that were identified by the SPC as important but were not prioritized as highly as the elements listed in Table 1 above (See SPC Report to the OPTN Board of Directors12). The MPSC evaluated each recommended measure and chose metrics for inclusion only if the metric met each of the following requirements:

- Measures aspects of care that are clearly within the authority of the OPTN
- Measures aspects of care that the transplant program can impact
- Has a clear desired outcome

---

• Does not require collection of new data or development of a new metric
• Measures a discrete aspect of transplant care provided by transplant programs
• Is risk-adjusted
• Incentivizes behaviors that will increase transplantation

Measures Considered But Not Selected

The MPSC evaluated measures suggested by the SPC, as well as additional measures suggested by MPSC members, using the requirements described above. Many of the suggested measures were eliminated from consideration based on a failure to meet one or more of the established requirements. The sections below explain the requirements used by the MPSC and address the MPSC’s basis for removing a number of the suggested measures from consideration.

Lack of OPTN Authority

The SPC recommended considering a number of pre-listing measures, including the percent of patients referred for evaluation that a program adds to the waitlist, the amount of time between the referral and the program’s listing decision, and an intent-to-treat analysis. Although MPSC members agreed that these are important aspects of a program’s performance, the MPSC acknowledged that the OPTN is not currently charged, by regulation or contract, to collect data regarding the pre-listing phase, and lacks other means to evaluate these areas. As a result, the MPSC removed those measures from consideration for this proposal.

Metrics Outside Transplant Program Control

Other measures the SPC recommended included the transplant rate, overall survival from listing, and time to transplant metrics. These metrics either describe system performance rather than transplant program performance, or incorporate data from multiple phases of transplant program patient care or phases of transplant care under the control of other organizations. For example, the MPSC believes the SRTR transplant rate metric is a good metric for patients to consider, since it describes how quickly a patient may be transplanted at a program. However, multiple factors are built into the transplant rate including waitlist mortality rate, active versus inactive status of candidates, deceased donor availability, living donor availability, OPO death to donor conversion, allocation policy, and the offer acceptance rate. Since the transplant rate metric includes factors influenced by OPO performance and multiple aspects of program performance, the transplant rate is not a good metric for transplant program performance monitoring; it would be hard to pinpoint and focus on areas for performance improvement. Similarly, the SRTR overall survival from listing metric includes 10 underlying metrics, some of which are outside the control of the program. The MPSC recognized that these metrics demonstrate how well the overall system is functioning and agrees that system metrics should be evaluated. However, because the MPSC is charged with evaluation of individual transplant program performance, the MPSC’s performance monitoring review process must focus on discrete metrics that transplant programs are able to sufficiently influence.

---

No Clearly Defined Data or Outcome

The MPSC eliminated from consideration any metric suggested by the SPC that did not have a clearly defined desired outcome, such as active versus inactive waitlist status, length of stay, and offer response time. The MPSC also did not consider metrics where the data was not clearly defined, such as offer response time.

In considering the SPC suggestion of active versus inactive waitlist status, the MPSC noted that this metric is not aligned with a specific goal or outcomes. Whether a candidate should be active or inactive and whether a program should have fewer or greater number of inactive candidates is unclear. For example, a transplant program’s active management of or failure to manage its waiting list could both result in a large number of inactive candidates on the program’s waiting list. In addition, the MPSC felt utilizing this metric might incentivize undesirable program behavior, such as maintaining a candidate as active when the candidate is not currently appropriate for transplant. The MPSC was concerned that such behavior could ultimately result in potential organ underutilization, if organ offers were increasingly made to candidates who were not in fact ready for transplant and the allocation system was therefore made to be less efficient.

The MPSC also considered a length of stay post-transplant measure to evaluate perioperative care. The MPSC concluded that, similar to the active versus inactive measure discussed above, a length of stay metric is not aligned with a specific goal or outcome and does not incorporate deaths prior to discharge. The length of stay varies based on the clinical circumstances and there is no clear goal for the optimal length of stay. In addition, there is no currently available metric incorporating a risk-adjusted comparison of length of stay to the expected national experience for patients with similar characteristics. Finally, use of a length of stay metric could incentivize transplant programs to release recipients from the hospital before it is clinically appropriate.

The MPSC considered reviewing offer response time, recognizing that shorter offer acceptance times could increase overall system efficiency. However, the MPSC rejected the use of this measure. Although offer time stamps are currently collected, there are some data quality concerns that could raise questions regarding use of this data for program evaluation. Additionally, there is no currently available measure for offer response time and the variation in offer response time is limited based on requirements in OPTN policy.15

Developing New Metrics

The MPSC determined it was important for any new performance monitoring system to utilize measures that are currently available. The time it would take to develop new measures and collect applicable data would significantly delay any progress on this project, and the MPSC felt it was imperative that action be taken quickly to improve the current system. At the same time, the MPSC acknowledges the potential benefit that new measures can have on this process. As new measures become available in the future, the MPSC is committed to considering whether those measures should be incorporated into the performance monitoring system, or should replace any of the existing measures. The MPSC discussed three important patient care aspects that fall within this category: a waiting list management process measure, a longer-term post-transplant outcome measure, and a post-transplant quality of life measure.

The MPSC noted specifically that a process measure that evaluates how a program interacts with its waiting list would be a good measure of quality waiting list management, and therefore provide a measure of a transplant program’s patient care. However, the MPSC could not determine an appropriate process metric for which there is currently available data that would incentivize active waitlist management. The MPSC considered evaluating transplant programs touchpoints with the UNet™ Waitlist application but determined that use of such a measure may encourage an unintended consequence of gratuitous inefficient interaction with the UNet™ Waitlist application. The MPSC will continue to evaluate whether an appropriate process measure can be developed to measure waitlist management.

The MPSC recognizes the benefit of evaluating transplant recipient long-term outcomes, noting that a five year measure could incentivize programs to improve efforts to maintain a relationship with recipients in providing follow-up care, and improve the transition of recipients to community care. However, the only currently available longer-term post-transplant outcome metric is the SRTR’s three-year graft and patient survival metric. Because the three-year survival rates are calculated using data from transplants performed four to six years earlier, the MPSC did not feel the data was timely enough to be utilized in performance monitoring. In other words, by the time a transplant program would be identified for performance review using those data, the problem either would have already have been going on for too long, or the problem may have resolved itself if the MPSC looked at more recent data. However, the SRTR is actively developing a five-year period prevalent metric. Period prevalent cohorts focus on more recent program performance while evaluating longer-term outcomes. The MPSC is supportive of this metric in concept, and will consider whether it can be incorporated into the performance monitoring system as soon as the metric is available.

The MPSC also acknowledges the importance of post-transplant recipient quality of life in addition to post-transplant graft or patient survival. However, there are no currently collected data points that are widely accepted proxies for recipient quality of life. The development of a post-transplant quality of life measure will require a significant commitment to identify, develop and test an appropriate measure. If additional investigation and study identifies relevant measures for recipient quality of life, the MPSC will consider whether the addition of such measures to the criteria for transplant program performance evaluation is appropriate.

**Risk Adjustment**

The MPSC endorsed the use of risk adjustment for any metrics used in the evaluation of transplant program performance. Risk-adjusted measures incentivize programs to list and transplant sicker patients and utilize organs from higher risk donors. When a program lists or transplants a patient with known risk factors, the number of expected events for that program increases by a greater amount than it would for a less-risky patient; as long as observed outcomes are equal, programs that list or transplant higher-risk patients can achieve a lowered observed-to-expected ratio. Some in the transplant community have suggested risk-adjustment inappropriately compares programs to each other. In fact, risk-adjustment compares a program against what would be expected to happen if that program performed like other

---


programs around the country that list similar candidates, accept offers for similar organs, and perform similar transplants. For example, the post-transplant survival model would only expect certain high-risk recipients to survive if similar high-risk patients were surviving at other transplant programs around the country. In its collective expertise, the MPSC felt that lack of risk-adjustment would in fact make transplant programs more risk-averse and could result in the unintended negative consequence of greater organ discard. Therefore, the MPSC eliminated from consideration any metric that did not include some level of risk-adjustment. However, the MPSC discussed anecdotal concerns within the transplant community about the comprehensiveness of the current risk-adjustment models. The MPSC fully supports working with the Scientific Registry of Transplant Recipients (SRTR) and the transplant community to identify clinical variables that can improve risk adjustment models.

**Use of CUSUM charts**

The MPSC evaluated the SPC’s suggestion to consider using cumulative sum control charts (CUSUMs) to evaluate post-transplant outcomes. CUSUMs are currently available for patient and graft survival rates, as well as offer acceptance rates. One perceived benefit of the CUSUMs is that they evaluate more recent data than the current two and a half year survival model cohort. By their design, CUSUM charts are effective at identifying programs with concerning trends in the short term. However, the MPSC was concerned that this may result in an increased number of programs identified for review based on short, “random” runs of failures whereas the longer-term cohort metrics might reveal satisfactory outcomes over a longer period of time. Although the MPSC recognizes the importance of the transplant program monitoring their CUSUM data to identify outcomes issues before they have the opportunity to accumulate, the additional data review burden and shorter-term sensitivity of the CUSUM metrics were seen by the MPSC as outweighing the benefits they might bring. In addition, by not using these metrics for the purposes of identifying underperforming programs, the MPSC hopes that the CUSUM data remain an important tool for programs to self-monitor their outcomes and potentially avoid longer-term performance issues.

**Measures Selected**

The following sections describe the metrics chosen by the MPSC to holistically evaluate transplant program performance and the basis for the MPSC’s decision.

**Pre-Transplant Waitlist Management**

Of the pre-transplant measures recommended by the SPC, only the waitlist mortality rate (or pre-transplant mortality rate) and offer acceptance rate met the MPSC’s required criteria. The MPSC assessed whether these measures sufficiently represent two distinct aspects of pre-transplant care. First, the Committee evaluated data provided by the SRTR, which showed a minimal correlation between the program outcomes on these two metrics. Additionally, after the MPSC established boundaries, the Committee reviewed data on programs that would be identified. The data showed that

---


20 As of July 6, 2021, waitlist mortality rate is now referred to as the pre-transplant mortality rate on the SRTR website and in the transplant program specific reports (PSRs). Prior to submission to the Board for approval, references to the names of metrics will be reviewed for consistency with the terminology used in reports by the SRTR.

of 27 programs that met the proposed criteria for these two metrics, no programs were identified by both.\textsuperscript{22}

The MPSC discussed the benefits and the disadvantages of use of the waitlist mortality rate to assess a program’s waitlisted candidate care. The waitlist mortality rate is risk-adjusted and has already been available to transplant programs for a significant time. It measures an aspect of transplant care post-listing, namely whether candidates listed at a transplant program gain the benefit of transplant by staying alive on the waiting list.\textsuperscript{23} On the one hand, the MPSC acknowledges often-communicated criticism that this metric is not useful for kidney transplant programs since they typically do not provide direct care to patients on the waiting list. Therefore, the health and mortality of patients on a kidney waiting list may be outside the control of the program. The MPSC discussed at length common misperceptions about the metric, such as the assertion that the waitlist mortality rate can be manipulated by simply adding many relatively healthy, low-risk patients to the waiting list, or the idea that adding sicker patients to the waiting list would adversely affect a program’s waitlist mortality rate. Some Committee members were concerned that these misperceptions would nevertheless deter programs from listing sicker patients, resulting in an unintended consequence of decreasing access to transplant. The Committee acknowledged that the risk adjustment would account for these behaviors appropriately. For example, the model would expect relatively healthy, low-risk patients to survive for a longer time on the waiting list and would expect sicker patients to not survive as long. A program’s metric would only be adversely affected if the healthy, low-risk patients did not survive while on the waitlist. A program’s metric would be positively impacted if a sicker patient survived longer than expected while on the waiting list.

Committee members also noted a number of benefits of use of the waitlist mortality rate. It would encourage programs to examine how to improve the care of candidates on the waiting list, potentially through activities like education and outreach to referring physicians. Additionally, utilizing this metric would encourage programs to examine how to actively manage the waiting list, through activities like a periodic re-evaluation of listed candidates for suitability for transplant. Evaluation of waitlist mortality, in combination with a reduced emphasis on post-transplant outcomes, could also incentivize more aggressive offer acceptance practices as studies have demonstrated that the probability of waitlist mortality increases after at least one declined offer.\textsuperscript{24,25,26,27,28,29} Use of the waitlist mortality rate metric could encourage review and improvement of systems issues that are barriers to getting patients transplanted before they die on the waiting list. Others noted that use of the metric could also

\textsuperscript{22} Data presented by UNOS staff to MPSC Performance Monitoring Enhancement Subcommittee on May 7, 2021. Available upon request.
\textsuperscript{26} Lai JC, Feng S, Roberts JP. An examination of liver offers to candidates on the liver transplant wait-list. Gastroenterology 2012; 143(5): 1261-1265.
discourage listing of patients who are unlikely to benefit from transplant. Finally, Committee members noted that some of the previous concerns that use of this metric would deter programs from listing sicker patients may no longer be as relevant based on the changes to broader distribution in each organ’s allocation system. If programs avoid adding sicker patients to the waiting list, the program is less likely to get offers and perform transplants. The MPSC ultimately determined that the waitlist mortality rate is the most effective currently available metric to measure waiting list candidate care.

Regarding offer acceptance practices, the MPSC noted that the offer acceptance rate metric has been available to programs via the SRTR for a number of years and is risk adjusted, and transplant programs have significant, if not total, control over this metric. The offer acceptance model is the most complex of the models built by the SRTR due to the large amount of available data. Therefore, the model adjusts for an extensive number of donor factors and recipient factors, sequence number of the candidate for which the offer is received, and candidate’s distance from the donor hospital. However, as with the waitlist mortality rate metric, the MPSC discussed at length common misperceptions about the organ offer acceptance rate metric in the community. One of the biggest misunderstandings seems to be around which offers are included in the metric; the MPSC feels it is important to note that programs are only evaluated on offers they receive and decline and that another program accepts and transplants. Offers are not included if the organ offered is not eventually transplanted. If a program never receives an offer due to the use of offer filters that screen their candidates off the match run, the program’s organ offer acceptance rate is not impacted.

Additionally, the MPSC noted that the percentage of offers accepted nationally is quite low, as shown in Table 2 below.

<table>
<thead>
<tr>
<th>SRTR PSR Cohort</th>
<th>Heart</th>
<th>Kidney</th>
<th>Liver</th>
<th>Lung</th>
<th>Pancreas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fall 2020</td>
<td>6.5%</td>
<td>0.76%</td>
<td>3.7%</td>
<td>4.9%</td>
<td>5.4%</td>
</tr>
<tr>
<td>Spring 2020</td>
<td>7.0%</td>
<td>0.8%</td>
<td>4.3%</td>
<td>4.9%</td>
<td>6.9%</td>
</tr>
</tbody>
</table>

The MPSC believes evaluating a transplant program’s offer acceptance rate will encourage behaviors that can increase the average organ offer acceptance rate, improve system efficiency and ultimately result in an increase in the number of transplants. First, it will encourage transplant programs to honestly evaluate what organs they are willing to accept for a candidate and use the offer filters and screening criteria in the Waitlist application to eliminate organ offers that the program would never accept. This should decrease the number of offers that must be made in order to place an organ. Evaluating offer acceptance will also encourage programs to actively manage their waiting lists in order to make sure that candidates who are listed as active are ready for transplant and that candidates who are not ready for transplant are placed in an inactive status. Encouraging the use of offer filters and screening criteria and active waiting list management will contribute to system efficiency in getting organs to the right patient more quickly, thereby streamlining the allocation process and decreasing ischemic time and organ underutilization. The use of offer acceptance rate in combination with a reduced emphasis on post-transplant outcomes will encourage transplant programs to accept more


organs, increasing the number of transplants to benefit more patients. Lastly, evaluating programs’ offer acceptance rates may even improve waitlist mortality. As noted above, studies have found that the probability of mortality on the waitlist increases when offers are declined.\textsuperscript{32,33,34,35,36,37} Being evaluated on offer acceptance will discourage programs from declining offers for transplantable organs, thereby decreasing candidates’ risk of mortality on the waiting list.

\textit{Post-Transplant Outcomes}

The MPSC identified two distinct phases of care for post-transplant recipient outcomes, perioperative care and postoperative care. Perioperative care is an initial period of more intensive patient care post-transplant. For purposes of MPSC measures, perioperative care incorporates list management, recipient selection, surgical care and the effectiveness of the multi-disciplinary team and care pathways prior to release for longer-term maintenance care. Postoperative care follows the release of a recipient to longer-term care and focuses on the transplant program’s ability to coordinate and provide recipient care for the long-term post-transplant. Based on the evaluation described below, the MPSC chose 90-day graft survival for the measure to evaluate a program’s perioperative phase and 1-year post-transplant graft survival conditional on 90-day graft survival for the measure to evaluate a program’s longer term postoperative phase. Both of these metrics would utilize the current 1-year post-transplant survival model cohort of two and a half years. Although there is more correlation between these two metrics than between the two metrics chosen for pre-transplant evaluation, the MPSC’s assertion that each of these metrics evaluates a distinct aspect of patient care is supported by the fact that out of 33 distinct programs identified by the proposed boundaries for these two metrics, only two programs were identified by both.\textsuperscript{38}

The MPSC focused on the currently available one-month, one-year and three-year post-transplant outcomes metrics. As discussed previously, the MPSC did not consider the three-year post-transplant outcomes metric because, as the metric is currently constructed, it includes transplants up to six years prior to the report date, a long period inappropriate for purposes of monitoring recent transplant program performance. The MPSC focused on developing the short-term perioperative care and longer-term postoperative metrics within the one-year post-transplant time frame. When considering the one-month and one-year metrics, the SRTR informed the MPSC that the SRTR could provide reports using an alternative time frame to assess short-term post-transplant outcomes. The SRTR also indicated it could produce a 1-year post-transplant outcome metric that is conditioned on whether the graft was functioning at the end of the short-term period.

\textsuperscript{34} Lai JC, Feng S, Roberts JP. An examination of liver offers to candidates on the liver transplant waitlist. \textit{Gastroenterology} 2012; 143(5): 1261-1265.
\textsuperscript{38} Data presented by UNOS staff to MPSC Performance Monitoring Enhancement Subcommittee on May 7, 2021. Available upon request.
In order to delineate the appropriate time frame for short-term perioperative care, the MPSC drew on the clinical expertise of its members and SRTR data illustrating the time period in which early graft losses and patient deaths leveled off. Although there are small variations among organs, the data established that early graft loss and patient death events leveled off around the 90-day mark for all organs, as seen in Figures 1 – 4 below.

**Figure 1:** Hazard Function for Heart Adult Graft Failure Through 3-Years Post-Transplant

**Figure 2:** Hazard Function for Kidney Adult Graft Failure Through 3-Years Post-Transplant
MPSC members confirmed, based on clinical experience, that this time period roughly coincided with the most intensive recipient care post-transplant for all organs. In order to ensure that the post-operative metric measures a distinct, independent phase of post-transplant care, the MPSC supports the use of a 1-year longer-term outcome metric that is conditional on graft function at the end of the 90-day period. The conditional 1-year metric cohort would only include those recipients whose graft was functioning at 90-days post-transplant. Using a conditional 1-year metric in conjunction with a 90-day short-term measure will help programs identify and focus on specific areas, either perioperative or postoperative, for improvement of recipient care. As previously stated, the MPSC supports the use of a one-year post-transplant survival conditional on 90-day survival metric initially while committing to evaluating whether to replace this measure with a longer-term post-transplant measure, including but not limited to the development of period prevalent cohorts.
The MPSC further considered whether it was necessary to continue to evaluate both post-transplant graft and patient survival. Use of either graft or patient survival would simplify the system by limiting the total number of metrics evaluated to four rather than six. The MPSC discussed the importance of patient survival as a reflection of a life saved and acknowledged that saving lives is the ultimate goal of transplantation. The Committee also discussed the necessity sometimes for patients to be re-transplanted in order to survive. However, the MPSC recognized that the graft survival model is the most comprehensive, in that it includes graft losses, patient deaths and re-transplants. Furthermore, the patient survival model excludes re-transplants and is not well suited for evaluation of kidney transplant programs, where a patient is likely to survive following the loss of a kidney graft. The MPSC felt that failing to capture kidney graft losses would constitute a substantial blind spot for an event with significant patient harm, for both the recipient who lost the graft and for another patient that did not receive a transplant. For these reasons, the MPSC recommended only evaluating graft survival for post-transplant outcomes.

An evaluation of 1-year post-transplant graft and patient flags over four recent reporting cycles found that the overwhelming majority of programs identified for MPSC review were identified for both graft and patient survival or for graft survival only. A small number of programs were identified for patient survival only as shown in Table 3 below.

<table>
<thead>
<tr>
<th>Table 3: Distribution of adult flags over four reporting cycles: SRTR PSR Spring 2019, Fall 2019, Spring 2020, Fall 2020.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Both Graft &amp; Patient Survival</strong></td>
</tr>
<tr>
<td>Kidney</td>
</tr>
<tr>
<td>Heart</td>
</tr>
<tr>
<td>Liver</td>
</tr>
<tr>
<td>Lung</td>
</tr>
</tbody>
</table>

However, many of the programs that were seemingly only identified for patient survival were in fact identified for both patient and graft survival during another reporting cycle, either in the four cycle period directly examined or in the reporting cycle (Fall 2018) immediately preceding the period examined. Table 4 below illustrates that 39 distinct programs had a patient survival only flag in one of the four reporting cycles referenced in Table 3 above. Of those 39 programs, only six were flagged for patient survival only for more than one cycle and were not also recently flagged for graft and patient survival or graft survival only in another recent cycle.


40 Scientific Registry of Transplant Recipients. MPSC flagged centers 202011.
Table 4: Examination of programs identified for patient survival only in at least one cycle

<table>
<thead>
<tr>
<th></th>
<th>Kidney</th>
<th>Heart</th>
<th>Liver</th>
<th>Lung</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recent graft/patient survival or graft survival flag. (In addition to patient flag)</td>
<td>8</td>
<td>4</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>One-time patient survival flag with no other recent flags.</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Fall 2020 patient survival flag only.</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>No graft/patient survival or graft survival flags but a patient survival flag for more than one cycle.</td>
<td>5</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Total programs with patient flags.</td>
<td>18</td>
<td>7</td>
<td>11</td>
<td>3</td>
</tr>
</tbody>
</table>

One of the kidney transplant programs identified for patient survival only in more than one cycle did not receive an inquiry after the MPSC applied the kidney transplant program operational rule requiring an additional evaluation of whether a program meets criteria following exclusion of higher risk transplants. The other four kidney transplant programs identified for patient survival only in more than one cycle were released from review in one year or less after receipt of initial response from the program suggesting the lack of significant MPSC concern with the programs’ performance. The one liver transplant program was identified under the current criteria for patient survival in two cycles. The program’s data for both cycles was close to the boundary of the current criteria and would not meet the proposed criteria. Based on this evaluation, the MPSC is confident that use of graft survival only will identify the heart, kidney, liver and lung programs with which the MPSC should engage.

For pancreas transplant programs, the MPSC proposes to continue the current practice of evaluating patient survival only. The SRTR does not currently produce a pancreas graft survival model. A new OPTN policy defining pancreas graft failure was implemented in February 2018 so there is not sufficient data following implementation of this new definition to produce a pancreas graft survival model. Once a graft survival model is developed, the MPSC will consider replacing the evaluation of pancreas patient survival with graft survival.

Establishment of Boundaries

Although the OPTN has the authority to perform ongoing, routine evaluation of the performance of every transplant program to identify potential risks to patient health and public safety under the OPTN Final Rule and the OPTN contract, the nature of MPSC performance review necessarily involves a significant commitment of the limited resource of MPSC peers. The OPTN receives data for the relevant metrics for all transplant programs, but has in the past and will continue to use boundaries for each metric that are designed to narrow the transplant programs that actively participate in an intervention with the MPSC to those outlier programs that are most likely to potentially pose a risk to patient health and public safety.

As part of this effort, the MPSC re-evaluated the current process for MPSC review of transplant program performance. In developing a new process, the MPSC emphasizes the importance of self-monitoring, self-examination and self-improvement as part of the performance monitoring process while also serving its oversight responsibility to ensure patient safety. In furtherance of these two goals, the
performance review process will include two tiers, the MPSC intervention or “red” zone, and a performance improvement or “yellow” zone. Transplant programs would only be required to interact with the MPSC if the program fell within the criteria for the MPSC intervention (red zone). For the MPSC intervention zone, the MPSC review process will be similar to the current process for review of one-year post-transplant outcomes. Transplant programs identified for performance review receive an initial inquiry regarding program structure, procedures and protocols, quality review processes, and plans for improvement followed by possible additional interactions with the MPSC based on review of that initial submission, such as additional requests for information, informal discussions or peer visits. Programs that fall within the performance improvement zone will not be obligated to interact with the OPTN. Therefore, the criteria for this zone are not included in the proposal. The MPSC may change the boundaries for the performance improvement zone over time. Because the performance improvement zone is not an OPTN Obligation, the boundaries for it are not proposed for inclusion in the Bylaws. However, the OPTN will make the performance improvement zone boundaries publicly accessible on its website. The MPSC is interested in receiving feedback on the performance improvement zone concept.

For the MPSC intervention zone, the MPSC is proposing independent boundaries for each metric and separate boundaries for adult and pediatric transplants; and proposing that each boundary apply to all organ types including heart, kidney, liver, lung and pancreas. As discussed earlier, the proposed boundary for the two post-transplant outcomes metrics will be applied to patient survival rather than graft survival for pancreas programs. The following sections provide information on the process used to determine appropriate boundaries, the alternatives discussed by the MPSC, and the boundary criteria chosen for the proposal.

**Process for Setting Boundaries**

The MPSC decided where to place the boundary for each metric based on a number of considerations. First, the MPSC wanted to focus its review on programs with clinically meaningful differences in performance from their peers. The MPSC felt that programs that are significant outliers would be most likely to need performance improvement assistance in order to avoid a potential risk to patient health or public safety. Second, the MPSC determined, for a number of reasons, that the proposed process should not increase the total number of programs identified for review, even though the number of metrics was increasing. The MPSC designed the current boundaries to have a 5% false positive rate, in order to have strong confidence that all programs in need of assistance were identified for review. In other words, the current system was intentionally designed in a way that would likely result in some programs being identified for review that are actually performing as expected. The MPSC decided to shift the focus of the new performance system to focus on programs that are outliers and most likely in need of help. This will identify a smaller number of programs in each metric and result in approximately the same cumulative number of reviews. Lastly, and perhaps most importantly, the MPSC acknowledged that increasing the number of programs identified for review might have the unintended consequence of dis-incentivizing transplantation.

Please note that the number of “flags” each cycle is not equivalent to the number of programs that will enter performance review during that cycle. Under the current system, one program is often identified during multiple reporting cycles and a program could be “flagged” for lower than expected survival on both pediatric and adult transplants, resulting in a much smaller number of new inquiries each cycle. For

---

example, Figure 5 below notes that out of 105 total “flags” for 1-year post-transplant survival in the Spring 2020 SRTR MPSC reports, only 28 programs (green bars) received an inquiry. Forty programs were already under review (light blue) and 24 had recently been released (teal) after having been “flagged” in previous cycles. 42

Figure 5: Number of Programs Flagged in Spring 2020 MPSC Reports and MPSC Action Based on Flag by Organ

The MPSC expects a similar phenomenon when the proposed criteria are implemented. It would be expected that a certain percentage of programs identified each cycle will have been identified in a previous cycle and under review or recently released. In addition, there could be a small number of programs that meet the criteria for more than one metric during a particular cycle.

Once the MPSC determined the new process should identify approximately the same number of total “flags” as the current system, the MPSC considered whether separate criteria should be established for smaller volume programs or for pediatric transplants. Although the use of the Bayesian methodology improves the ability of boundaries to identify potentially underperforming medium and small volume programs, the ability to identify potentially underperforming small volume programs decreases as the probability (or certainty) that a program will be above a particular rate ratio or hazard ratio increases. 43

The current MPSC boundaries for 1-year post-transplant survival address this concern by including one boundary with a higher probability (greater than 75% probability that a program’s patient or graft survival hazard ratio is greater than 1.2) and a second boundary with a much lower probability (greater than 10% probability that the hazard ratio is greater than 2.5). These criteria result in boundaries that are sloped as illustrated in Figure 6 below:

42 Data based on an evaluation of the Spring 2020 SRTR MPSC reports presented by UNOS staff at May 7, 2021 MPSC Performance Monitoring Enhancement Subcommittee meeting.
Instead of creating separate criteria to capture smaller volume programs, the MPSC is proposing criteria that includes a 50% probability that a program is above, or below for offer acceptance, a certain rate ratio or hazard ratio for each metric. The 50% probability flattens the slope to reduce the effect of transplant volume size, waiting list size or number of offers on the process for identification of potentially underperforming programs. Using the 90-day graft survival proposed boundaries as an example, the slope of the proposed boundary is illustrated in the plot below. **Figure 7** below illustrates the proposed boundary for adult transplants in dark purple with the current MPSC boundaries superimposed in lighter purple.

**Figure 7**: Plot of Proposed Adult 90-Day Graft Survival Boundary

Both of these figures contain circles for only those programs that are above the national average of 1.0.

---

44 Scientific Registry of Transplant Recipients. MPSC: Considerations in choosing a ‘good’ metric [presentation to MPSC November 5, 2019]. Available upon request.

The MPSC proposes separate boundaries for adult and pediatric transplants. The SRTR produces separate models for evaluation of adult and pediatric transplants.\(^{46}\) Due to the overall lower volume and lower number of events for pediatric transplants, the level of certainty about the results for pediatric programs is lower; therefore, the hazard ratios for the pediatric boundaries for the post-transplant 90-day graft survival and 1-year graft survival conditional on 90 day graft survival are slightly lower and the rate ratio for offer acceptance is slightly higher than the proposed boundaries for adult transplants.

Finally, the MPSC considered how the “flags” should be distributed across the four metrics. The MPSC determined that the appropriate distribution would be a 50/50 split of the total number of “flags” across all organ types between the pre-transplant and post-transplant metrics. The MPSC believes that the pre-transplant and post-transplant outcomes are of equal importance to the patient experience and therefore, a 50/50 split is appropriate. Additionally, the requested number of “flags” for pre-transplant and post-transplant outcomes should be distributed across all organs so the resulting reviews would be concentrated where the most variation from the average exists.

Following determination of these parameters for the boundaries, the MPSC asked the SRTR to perform a data analysis that would produce optimal boundaries for each metric and identify the desired number of programs. The SRTR developed a tool for the MPSC to consider various boundaries, including the optimal boundaries that would identify the requested number and distribution of “flags,” and to evaluate program data for programs that would likely be identified for review under the various boundaries.\(^{47}\) MPSC members were able to use their clinical and subject matter expertise to review the relevant data for the programs identified, as well as those that fell immediately below the boundary, to determine if the proposed boundaries appropriately captured programs that were significant outliers and likely in need of performance improvement assistance in order to avoid a potential risk to patient health and public safety.

**Alternatives Considered**

The MPSC discussed the advantages and disadvantages of use of a composite score or independent boundaries for each metric. One potential benefit of a composite score is that it combines a program’s results into one overall simple score, which could allow high performance on one or more metrics to counterbalance lower performance on another metric. However, a composite score makes the criteria more complex, is difficult to interpret, and does not identify specific areas for improvement. In addition, there is a possibility that the composite score could mask a true patient safety risk in one aspect of a transplant program’s patient care. If the MPSC has succeeded in identifying measures that each represent a discrete and independent aspect of transplant care, a separate boundary for each independent metric will clearly allow the MPSC, as well as programs, to most clearly identify specific aspects of care in which the program has opportunity for improvement.

Some members of the transplant community have suggested that programs only be identified for performance review if they fall below a fixed survival floor for one-year patient and graft survival.\(^{48}\) For

---


example, a kidney program would only be identified for review if its observed (raw) post-transplant one-year patient and graft survival fell below 90 percent, or another fixed number. Using a fixed floor with unadjusted measures would mean that programs would not see any statistical benefit from transplanting sicker patients or using organs from higher risk donors; all programs would be expected to achieve the same observed survival rate, regardless of the acuity of their patients or the quality of the donor organs they transplant. In other words, there would be no room for error, particularly in any low-risk transplants. The MPSC discussed whether to utilize a fixed-floor approach when setting the boundaries for each metric. However, as described in the previous sections, the MPSC felt that risk-adjustment is an important aspect of incentivizing listing and transplantation of higher-risk recipients and utilizing organs from higher-risk donors. Because a fixed floor approach does not utilize risk adjustment, the MPSC felt it would have the unintended consequence of promoting risk averse behavior.

The MPSC reviewed data provided by the SRTR and explored setting separate boundaries for each organ type. The MPSC noted that choosing organ-specific boundaries could result in an inequitable distribution of programs under review based on organ type, identifying some programs for review and not others with similar performance. Applying the same identification criteria to programs of all organ types incorporates the extent of variation for each organ type for each metric resulting in identification of outliers, regardless of organ type, for each metric. In addition, the MPSC found it difficult to achieve the goal of identifying the same or fewer programs when setting separate boundaries for each organ type. Based on these considerations, the MPSC proposes the establishment of the same identification criteria for each of the four proposed metrics to be applied across all organ types combined, similar to the current post-transplant survival identification criteria.

The MPSC considered alternative methods for review of programs that perform pediatric transplants, including requiring the reporting of all pediatric graft losses or deaths in a manner similar to the requirement for reporting living donor events or performing routine periodic limited reviews of programs that perform pediatric transplants to determine if a potential risk to patient health or public safety exists. The MPSC rejected the requirement to report all pediatric graft losses or deaths for a number of reasons. The MPSC concluded that the volume of reports annually would pose an unacceptable burden for programs that perform pediatric transplants and for review by the MPSC. From 2014 – 2020, there were between 50 and 63 pediatric patient deaths per year with a range for individual programs between 0 and 7 pediatric patient deaths. There were between 77 and 112 pediatric graft losses with a range for individual programs between 0 and 9 for that same time period. More importantly, the MPSC was concerned that a requirement to report all deaths or graft losses would likely create a disincentive to list and transplant higher risk pediatric patients. Finally, concern was raised that singling out pediatric programs rather than applying a different process to all small volume programs, adult and pediatric, was unsupportable since the challenges for identification of underperforming pediatric components are related to the generally lower volume of pediatric transplants.

The MPSC also considered the possibility of routine periodic reviews of performance data for all small volume programs, adult and pediatric. The MPSC found this proposed solution interesting and would like to explore this option further. However, the MPSC was concerned that, without a more real-time mechanism to identify small volume programs for review, a routine periodic review may result in delay in capturing a risk to patient health and public safety. The MPSC decided, for purposes of this proposal,

that the prudent, evidenced based path is to use the same process to identify program underperformance for both adult and pediatric transplants, with a slightly more inclusive boundary for pediatric transplants to counteract the effects of lower volume of transplants and events in this population. In addition, a routine periodic review of small volume program data including a request for programs to voluntarily provide information is included as part of the post-implementation evaluation plan to determine the feasibility of this process and to evaluate the effectiveness of the proposed criteria for adult and pediatric transplants to identify underperforming small volume programs.

**Adult Criteria**

The boundaries proposed for programs that perform adult transplants are:

The probability that the transplant program meets any of the following criteria is greater than 50% for adult transplants:

a. The transplant program’s waitlist mortality rate ratio is greater than 1.75 during a 2 year period.
b. The transplant program’s offer acceptance rate ratio is less than 0.30 during a 1 year period.
c. The transplant program’s 90-day post-transplant graft survival hazard ratio is greater than 1.75 during a 2.5 year time period. For pancreas transplant programs, 90-day post-transplant patient survival hazard ratio is greater than 1.75 during a 2.5 year period.
d. The transplant program’s 1-year post-transplant graft survival conditional on 90-day post-transplant graft survival hazard ratio is greater than 1.75 during a 2.5 year period. For pancreas transplant programs, 1-year post-transplant patient survival conditional on 90-day post-transplant patient survival hazard ratio is greater than 1.75 during a 2.5 year period.

For waitlist mortality, 90-day graft survival and 1-year post-transplant graft survival conditional on 90-day post-transplant graft survival, the rate or hazard ratio for worse than average performance is greater than 1.0. As explained previously, unlike heart, kidney, liver and lung, pancreas transplant programs will be evaluated based on 90-day post-transplant patient survival and one year post-transplant patient survival conditional on 90 day post-transplant patient survival because there is no current SRTR pancreas post-transplant graft survival model. For offer acceptance, the rate ratio for worse than average performance is less than 1.0. Therefore, for offer acceptance, a program with an offer acceptance rate ratio of 0.25 would be identified for review based on the criteria of a 50% probability that the offer acceptance rate ratio is less than 0.30.

The application of these criteria to the SRTR Spring 2020 Program Specific Report (PSR) data would result in a total of 62 adult flags for heart, kidney, liver and lung, compared to an average 68.5 adult flags for heart, kidney, liver and lung over four reporting cycles (Spring 2019, Fall 2019, Spring 2020 and Fall 2020). **Table 5** below provides the breakdown of transplant programs identified by metric and organ type for heart, kidney, liver and lung.
Table 5: Number of Programs Identified for Adult Transplants Outcomes by the Proposed Metrics by Metric and Organ Type Using Data from Spring 2020 SRTR PSR.

<table>
<thead>
<tr>
<th>Adult Proposed Boundaries</th>
<th>Heart</th>
<th>Kidney</th>
<th>Liver</th>
<th>Lung</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waiting List Mortality - 50% Probability RR &gt; 1.75</td>
<td>5</td>
<td>0</td>
<td>3</td>
<td>5</td>
<td>13</td>
</tr>
<tr>
<td>Offer Acceptance – 50% Probability RR &lt; 0.30</td>
<td>1</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>90-day Graft Survival – 50% Probability HR &gt; 1.75</td>
<td>3</td>
<td>10</td>
<td>4</td>
<td>2</td>
<td>19</td>
</tr>
<tr>
<td>Conditional 1-year Graft Survival – 50% Probability HR &gt; 1.75</td>
<td>3</td>
<td>9</td>
<td>1</td>
<td>3</td>
<td>16</td>
</tr>
<tr>
<td>Total</td>
<td><strong>12</strong></td>
<td><strong>25</strong></td>
<td><strong>13</strong></td>
<td><strong>12</strong></td>
<td><strong>62</strong></td>
</tr>
</tbody>
</table>

The variation in the number of organ programs identified by each metric is due to level of variability of program performance on the metric for each organ. Lower variability among organ programs for a particular metric results in fewer outliers. For example, lack of significant variability in the waitlist mortality performance of kidney programs results in zero kidney programs being identified for waitlist mortality.

The application of these criteria to the SRTR Spring 2020 Program Specific Report (PSR) data would result in a total of seven adult flags for pancreas, compared to an average six adult flags for pancreas over four reporting cycles (Spring 2019, Fall 2019, Spring 2020 and Fall 2020). The seven pancreas programs include three identified for waiting list mortality, four for offer acceptance, zero for 90 day patient survival and zero for conditional 1 year patient survival.

The following plots of the boundaries for each metric provide a visual representation of the level of underperformance that would result in being identified for MPSC performance review. Tables of the data for programs identified by each of the four metrics can be found in Appendix A.

**Adult Waitlist Mortality**

Figure 8 below includes a circle for all heart, kidney, liver, and lung programs. The dark purple shaded area is the proposed boundary and the dark and light purple combined shaded area is the current MPSC boundary for comparison purposes. An observed hazard ratio of 1.0 is average, programs below 1.0 are performing better than average and programs above 1.0 are performing worse than average.
Adult Offer Acceptance

Figure 9 below includes a circle for all heart, kidney, liver, and lung programs. The purple shaded area is the proposed boundary. An observed hazard ratio of 1.0 is average, programs above 1.0 are performing better than average and programs below 1.0 are performing worse than average.

Adult 90-day Graft Survival

Figure 10 below includes a circle for all heart, kidney, liver, and lung programs. The dark purple shaded area is the proposed boundary and the dark and light purple combined shaded area is the current MPSC boundary for comparison purposes. An observed hazard ratio of 1.0 is average, programs below 1.0 are performing better than average and programs above 1.0 are performing worse than average.
Adult 1-year Post-transplant Graft Survival Conditional on 90-day Post-transplant Graft Survival

Figure 11 below includes a circle for all heart, kidney, liver, and lung programs. The dark purple shaded area is the proposed boundary and the dark and light purple combined shaded area is the current MPSC boundary for comparison purposes. An observed hazard ratio of 1.0 is average, programs below 1.0 are performing better than average and programs above 1.0 are performing worse than average.

Pediatric Criteria

The boundaries proposed for heart, kidney, liver and lung programs that perform pediatric transplants are:

The probability that the transplant program meets any of the following criteria is greater than 50% for pediatric transplants:
a. The transplant program’s waitlist mortality rate ratio is greater than 1.75 during a 2 year period.
b. The transplant program’s offer acceptance rate ratio is less than 0.35 during a 1 year period.
c. The transplant program’s 90-day post-transplant graft survival hazard ratio is greater than 1.60 during a 2.5 year period.
d. The transplant program’s 1-year post-transplant graft survival conditional on 90 day post-transplant graft survival hazard ratio is greater than 1.60 during a 2.5 year period.

The pediatric boundary for waiting list mortality is the same as the adult boundary. For the other three metrics, the pediatric boundary is set slightly lower for the post-transplant graft survival metrics and slightly higher for the offer acceptance metric. For waitlist mortality, 90-day graft survival and 1-year post-transplant graft survival conditional on 90-day post-transplant graft survival, the rate or hazard ratio for worse than average performance is greater than 1.0 where for offer acceptance, the rate ratio for worse than average performance is less than 1.0. Therefore, for offer acceptance, a program with an offer acceptance rate ratio of 0.25 would be identified for review based on the criteria of a 50% probability that the offer acceptance rate ratio is less than 0.35.

No criteria are proposed for pancreas pediatric transplants due to the low volume of pancreas pediatric candidates and transplants nationwide. The SRTR does not produce data for pancreas pediatric post-transplant patient survival because there are too few pancreas pediatric transplants and pediatric recipient deaths to calculate meaningful statistics. In 2020, there were 23 pancreas and kidney/pancreas pediatric transplants nationwide with four deaths reported as of July 23, 2021. From 2017 2018, and 2019, there were 31, 32 and 21 pancreas and kidney/pancreas pediatric transplants respectively nationwide with three, six and four deaths reported within 1 year post-transplant. In addition, due to the low volume of pancreas pediatric candidates, waitlist mortality and offer acceptance rates are available for a very small number of programs. On July 25, 2021, there were 51 pancreas pediatric candidates on the U.S. waiting list at approximately 11 transplant programs.

The application of these criteria to the SRTR Spring 2020 PSR data would result in a total of 29 pediatric flags for heart, kidney, liver and lung, compared to an average 27 flags for heart, kidney, liver and lung over four reporting cycles (Spring 2019, Fall 2019, Spring 2020 and Fall 2020). Table 6 below provides a breakdown by metric and organ type for heart, kidney, liver and lung.

<table>
<thead>
<tr>
<th>Pediatric Proposed Boundaries</th>
<th>Heart</th>
<th>Kidney</th>
<th>Liver</th>
<th>Lung</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waiting List Mortality - 50% Probability RR &gt; 1.75</td>
<td>8</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Offer Acceptance – 50% Probability RR &lt; 0.35</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>90-day Graft Survival – 50% Probability HR &gt; 1.60</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Conditional 1-year Graft Survival – 50% Probability HR &gt; 1.60</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>15</strong></td>
<td><strong>6</strong></td>
<td><strong>5</strong></td>
<td><strong>3</strong></td>
<td><strong>29</strong></td>
</tr>
</tbody>
</table>

The following plots of the boundaries for each metric provide a visual representation of the level of underperformance that would result in being identified for MPSC performance review. Tables of the data for programs identified by each of the four metrics can be found in Appendix A.
Pediatric Waitlist Mortality

**Figure 12** below includes a circle for all heart, kidney, liver, and lung programs. The dark purple shaded area is the proposed boundary and the dark and light purple combined shaded area is the current MPSC boundary for comparison purposes. An observed hazard ratio of 1.0 is average, programs below 1.0 are performing better than average and programs above 1.0 are performing worse than average.

![Figure 12: Plot of Proposed Pediatric Waitlist Mortality Boundary](image)

Pediatric Offer Acceptance

The below **Figure 13** includes a circle for all heart, kidney, liver, and lung programs. The purple shaded area is the proposed boundary. An observed hazard ratio of 1.0 is average, programs above 1.0 are performing better than average and programs below 1.0 are performing worse than average.
Pediatric 90-day Graft Survival

The below Figure 14 includes a circle for all heart, kidney, liver, and lung programs. The dark purple shaded area is the proposed boundary and the dark and light purple combined shaded area is the current MPSC boundary for comparison purposes. An observed hazard ratio of 1.0 is average, programs below 1.0 are performing better than average and programs above 1.0 are performing worse than average.

Pediatric 1-year Post-transplant Graft Survival Conditional on 90-day Post-transplant Graft Survival

The below Figure 15 includes a circle for all heart, kidney, liver, and lung programs. The dark purple shaded area is the proposed boundary and the dark and light purple combined shaded area is the current MPSC boundary for comparison purposes. An observed hazard ratio of 1.0 is average, programs
below 1.0 are performing better than average and programs above 1.0 are performing worse than average.

**Figure 15: Plot of Proposed Pediatric 1-year Post-Transplant Graft Survival Conditional on 90-day Graft Survival**

Review of Programs Identified in MPSC Intervention zone

Transplant program identification using the above criteria for the MPSC intervention or “red” zone does not in and of itself indicate that a transplant program poses a risk to patient health or public safety. The criteria are designed to trigger a MPSC inquiry and interaction with the transplant program to gather information to determine if further interaction is needed to help the transplant program avoid risk to patient health or public safety as described in more detail in the Member Compliance section below.

Addition of Peer Visit Section

The MPSC uses peer visits for all manner of performance and compliance issues as a tool to help transplant programs improve. Although there is a current reference in Appendix D to peer visits, the OPTN bylaws have not previously included a description of the peer visit process and member expectations. The MPSC is taking this opportunity to include language in the bylaws describing peer visits, thereby providing more transparency to members on the role of peer visits in MPSC reviews. The MPSC proposes the inclusion of the peer visit section in Appendix M: Reviews and Actions since this placement is consistent with the description of other MPSC review tools such as informal discussions. Other administrative revisions to Appendix M: Reviews and Actions are proposed in order to ensure consistency with the proposed revisions to Appendix D.13.A and the new proposed peer visit bylaw section.

Definitions Revisions

This proposal also includes a few administrative revisions to Appendix N: Definitions. The MPSC proposes to remove definitions of two defunct standing MPSC subcommittees, the Performance Analysis and Improvement Subcommittee (PAIS) and the Policy Compliance Subcommittee (PCSC), from the OPTN bylaw definitions. These two subcommittees were disbanded in 2018. In addition, the MPSC is proposing revisions to the definition of the Scientific Registry of Transplant Recipients (SRTR) definition
to remove specific references to the patient and graft survival rates and to mirror language from the background information on the Mission, Vision and Values on the SRTR website.

**NOTA and Final Rule Analysis**

This proposal is provided under the authority of the OPTN Final Rule, which states “[t]he OPTN shall design appropriate plans and procedures, including survey instruments, a peer review process, and data systems, for purposes of: . . . (iii) Conducting ongoing and periodic reviews and evaluations of each member OPO and transplant hospital for compliance with these rules and OPTN policies.” One component of the OPTN’s ongoing and periodic reviews and evaluations of OPOs and transplant hospitals is performance monitoring. This responsibility is further defined by the OPTN Contract Task 3.6

**OPTN member compliance and performance monitoring, quality improvement, and sanctioning,** which states:

The Contractor shall monitor OPTN member performance, including threats to patient health and public safety, maintain and develop efforts to improve OPTN member performance, and impose sanctions when warranted.

The Contractor shall develop processes to:

- monitor and review OPTN member performance, including threats to patient health and public safety;
- evaluate, assess, and monitor over time all OPTN members for compliance with the requirements of NOTA, the OPTN final rule, OPTN Bylaws and policies;
- educate and encourage OPTN member compliance with the requirements of NOTA, the OPTN final rule, OPTN Bylaws, and OPTN policies; and
- Promote member performance improvement to meet OPTN strategic planning goals as identified in Task 3.2.7.

The Contractor shall ensure that these processes encourage member self-reporting of potential compliance problems and provide incentives to report issues by assisting members in identifying root causes of issues and developing appropriate corrective actions.

In the event OPTN members are unable to increase compliance, improve performance, or mitigate threats to patient health or public safety, or unless otherwise determined to be appropriate, the Contractor shall develop processes consistent with the requirements of NOTA, the OPTN final rule, OPTN Bylaws, and OPTN policies to:

- impose OPTN sanctions as determined by the OPTN MPSC and BOD; and
- refer members to the Secretary when federal sanctions may be warranted.

Performance monitoring is the OPTN’s approach to identifying OPOs and transplant programs that are not performing according to key metrics that may implicate a patient safety concern. To efficiently identify and evaluate the transplant programs most likely in need of assistance to avoid potential risks to patient health and public safety, the MPSC proposes these evidenced-based boundaries for the performance review metrics; programs that fall outside of a boundary will be required to participate in the performance review process.

---

50 42 C.F.R. §121.10 (b)(1)(iii)
51 Organ Procurement and Transplantation Network; HHSH250201900001C. April 1, 2019.
Implementation Considerations

Member and OPTN Operations

*Operations affecting Transplant Hospitals*

Transplant hospital members will need to be familiar with the proposed new metrics for transplant program performance monitoring and the MPSC’s review process. Transplant hospital members should review the data currently available for each transplant program via the member’s private SRTR site, to assess whether a program is likely to be identified for review once the proposal is implemented. Though the MPSC has not reviewed programs’ pre-transplant data, programs’ offer acceptance and waitlist mortality data are currently provided on the SRTR private site for review by the program. Upon approval, members will continue to be able to access information on whether their programs meet MPSC criteria on the members’ private SRTR sites.

*Operations affecting Histocompatibility Laboratories*

This proposal is not anticipated to affect the operations of histocompatibility laboratories.

*Operations affecting Organ Procurement Organizations*

This proposal is not anticipated to affect the operations of organ procurement organizations.

*Operations affecting the OPTN*

The proposed metrics will be implemented based on the following timeline:

- 90-day graft survival and 1-year graft survival conditional on 90-day survival post-transplant outcomes criteria will be implemented in the first SRTR reporting cycle that occurs at least 6 months after approval by the OPTN Board of Directors.
- Offer acceptance criteria will be implemented in the SRTR reporting cycle that occurs at least 18 months after approval by the OPTN Board of Directors.
- Waitlist mortality criteria will be implemented in the SRTR reporting cycle that occurs at least 30 months after approval by the OPTN Board of Directors.

The OPTN will provide members with notice of pending implementation approximately 6 months prior to implementation to coincide with the release of the SRTR PSR that immediately precedes the effective date of use of the metric for MPSC review.

Because the MPSC’s transplant program performance review process has historically focused on post-transplant patient and graft survival, the MPSC feels it is appropriate to replace the current 1-year patient and graft survival metrics with the proposed 90-day graft survival and 1-year-conditional-on-90-day graft survival metrics as soon as the SRTR is able to provide the updated reports to the MPSC. Once the new post-transplant metrics are implemented, the MPSC will release from review any program that is no longer identified under the new system. The MPSC will collaborate on a voluntary basis with any member released from review that requests further assistance. The MPSC will continue to monitor any program that was previously under review and is also identified for review under the new criteria.
The MPSC will recommend that the Board of Directors delay the implementation of the proposed pre-transplant metrics to allow programs time to better understand the metrics, review their applicable data and practices, and make changes as desired. Specifically, the pre-transplant metrics will not be implemented until at least one complete cohort has passed, after the OPTN Board of Directors approves the proposal. The organ offer acceptance metric is calculated using a 12-month interval, and is reported six months after conclusion of the 12-month interval. Therefore, the organ offer acceptance metric will be implemented no sooner than 18 months after approval by the OPTN Board of Directors. Similarly, the waitlist mortality metric is calculated using a 24-month interval and is also reported six months after the conclusion of the 24-month interval. The waitlist mortality metric will be implemented no sooner than 30 months after approval by the OPTN Board of Directors. This will ensure the MPSC will only evaluate programs based on transplant program performance using data collected after the OPTN Board of Directors has approved the proposed metrics.

Prior to implementation of the organ offer acceptance and waitlist mortality criteria, the OPTN will notify programs that would be identified by these criteria that the programs will be identified for review once the criteria are implemented. The OPTN may ask these programs to voluntarily provide information to the OPTN for use in evaluation of the criteria and for development of resource materials and appropriate areas of inquiry. The OPTN will also collaborate with high performing programs to identify effective practices and develop resources.

The OPTN will also develop education and resources to prepare MPSC members to review programs identified under the new criteria and promote consistency in performance reviews.

Prior to implementation, the OPTN will provide educational offerings to help programs understand how various scenarios may impact each metric, and how to find and interpret data available on the SRTR private sites.

**Projected Fiscal Impact**

This proposal is projected to have a fiscal impact on the OPTN and transplant hospitals, but it is not anticipated to have any fiscal impact on organ procurement organizations or histocompatibility laboratories.

**Projected Impact on Transplant Hospitals**

Transplant hospital members will need to be familiar with the proposed new metrics for transplant program performance monitoring and the MPSC’s review process. Transplant hospital members should review the data currently available for each transplant program via the member’s private SRTR site, to assess whether a program is likely to be identified for review once the proposal is implemented. Though the MPSC has not reviewed programs’ pre-transplant data, programs’ offer acceptance and waitlist mortality data are already provided on the SRTR private site. Upon approval, members will continue to be able to access information on whether their programs meet MPSC criteria on the members’ private SRTR sites.

**Projected Impact on the OPTN**

This proposal is not anticipated to require any IT programming. Member Quality anticipates 600 implementation hours to develop appropriate areas of inquiry for the new metrics and resource materials for members.
Post-implementation Monitoring

Member Compliance

While the metrics and criteria used to identify transplant programs for MPSC engagement would change under this proposal, the review and engagement process will not substantially change. The OPTN will continue to receive reports from the SRTR twice a year that assess each transplant program’s performance against the new metrics and criteria and will use these reports to identify transplant programs for MPSC engagement. Member Quality staff will continue to send inquiries on behalf of the MPSC to a transplant program identified for engagement in order to request information about the program, such as:

- Program structure
- Procedures and protocols
- Quality review processes
- Plans for improvement

The MPSC will continue to review the information submitted by the program and may request that the member submit additional information about certain aspects of the program or submit a plan for quality improvement. The MPSC may also request that a member participate in additional engagement with the MPSC, such as an informal discussion or a peer visit. In rare circumstances where the MPSC identifies a potential ongoing risk to patient health or public safety, the MPSC may request that a member inactivate or withdraw a transplant program or a component of a program to mitigate the risk.

A performance improvement zone will be established operationally by the MPSC. The OPTN will make the performance improvement zone boundaries publicly accessible on its website. Programs that fall within the performance improvement zone will receive a letter informing the program that they are trending towards the MPSC intervention zone; encouraging the program to evaluate their performance for areas of improvement, if they have not already done so; and offering performance improvement assistance from a catalog of services, if desired. A program that falls within the performance improvement zone will not be obligated to interact with the OPTN. Therefore, the criteria for this zone are not included in the proposal.

The assistance offered will be drawn from the OPTN Individualized Member Focused Improvement (IMFI) catalog of services including:

- Education and training services either remotely or on-site on various topics such as the UNet\textsuperscript{SM} Data Portal tool, root cause analysis and corrective action plan reviews, process mapping and change management
- Quality and performance improvement services such as process mapping, customized coaching sessions with UNOS Research staff and guidance on PDSA worksheet
- Peer and subject matter expert engagements such as peer mentoring and connecting with other members to work together on similar issues.

The services available to members through the performance improvement zone and individual member requests will continue to develop and evolve.
Bylaw Evaluation

This bylaw will be formally evaluated at least annually post-implementation. Due to the staged implementation timeline and variations in the cohort periods, the evaluation metrics included in each annual evaluation report may vary. In addition to evaluating the effectiveness of this proposal to identify any needed adjustments as described below, the MPSC will continue to consider improvements to the transplant program performance review system through the consideration of new measures that may become available in the future or additional enhancements to the process for review and collaborative improvement assistance offered to OPTN members.

The following questions, and any others subsequently requested by the Committee, will guide the evaluation of the proposal after implementation:
- Have the new criteria contributed to a change in the number of transplants?
- Have the new criteria affected transplant program listing practices?
- Have the new criteria contributed to a change in offer acceptance rates?
- Have the new criteria contributed to a change in waitlist mortality rates?
- Have the new criteria contributed to changes in the aforementioned metrics with respect to patient populations associated with risk (e.g., high-KDPI donors) or demographics (e.g., age, ethnicity)?
- Are the new criteria effective at identifying small volume transplant programs with potential patient health and public safety issues?

Does MPSC engagement result in sustained improvement in waitlist mortality, offer acceptance and 1-year post-transplant graft survival?

To help answer the above questions, the following metrics, and any others subsequently requested by the Committee, will be evaluated as data become available for pre- and post-bylaw implementation.

- National mean utilization through organ yield rates for each organ (Heart, Kidney, Liver, Lung and Pancreas) before and after implementation.
- Number of waiting list additions before and after implementation including:
  - National mean listing rate for each organ (Heart, Kidney, Liver, Lung and Pancreas)
  - Variability across programs by organ (Heart, Kidney, Liver, Lung and Pancreas)
  - Variability based on risk stratification (e.g., MELD, dialysis time), and demographics (e.g., age, ethnicity)
- Offer Acceptance rates before and after implementation including:
  - National mean acceptance rate by organ (Heart, Kidney, Liver, Lung and Pancreas)
  - Variability across programs by organ (Heart, Kidney, Liver, Lung and Pancreas)
  - Variability based on risk stratification and demographics
- Waitlist mortality rates before and after implementation including
  - National mean waitlist mortality rate by organ (Heart, Kidney, Liver, Lung and Pancreas)
  - Variability across programs by organ (Heart, Kidney, Liver, Lung and Pancreas)
  - Variability based on risk stratification and demographics
- Number of graft failures (or patient deaths for pancreas) during the first year post-transplant before and after implementation
  - National 1-year survival rates by organ transplanted (Heart, Kidney, Liver, Lung and Pancreas)
  - Variability across programs by organ (Heart, Kidney, Liver, Lung and Pancreas)
Variability based on risk stratification and demographics

The MPSC will also evaluate the effectiveness of the criteria and the MPSC interactions with programs through monitoring of:

- Number of programs identified by each metric and the number of unique programs identified in each semiannual report
- Member feedback obtained during and following MPSC engagement
- Evaluation of improvement at programs with which the MPSC engaged and if that improvement was sustained following release from review
- Periodically review data of and collect information from programs that perform less than one transplant per month on average to evaluate the effectiveness of the criteria to identify potential issues at smaller volume programs and consider appropriate alternatives, if needed.

Though this proposal does not include any changes to data collection or recommendations for changes to the existing risk-adjustment models created by the SRTR, the MPSC intends to proactively collect and evaluate data that may help inform changes to those areas. Specifically, during each performance review, the MPSC will evaluate whether any data variables that are not currently collected or included in the risk-adjustment models seem to have affected program outcomes. The MPSC will include this analysis in its annual evaluation report.

**Conclusion**

In an effort to holistically evaluate transplant program performance, the MPSC proposes to use four separate metrics that each measure a distinct aspect of transplant program patient care – waitlist mortality rate measuring waiting list patient care, offer acceptance rate measuring offer acceptance practices, 90-day post-transplant graft survival measuring peri-operative care and 1-year post-transplant graft survival conditional on 90-day graft survival measuring post-operative care. The MPSC chose the proposed metrics based on an evaluation that required each metric to measure aspects of care that are clearly within the authority of the OPTN; measure aspects of care that the transplant program can impact; have a clear desired outcome; not require the collection of new data or development of a new metric; be risk-adjusted; and incentivize behaviors that increase transplantation. The boundaries proposed for the metrics are focused on identifying clinically meaningful outlier transplant programs that potentially pose a risk to patient health or public safety. Based on the differences in transplant volume and number of events in pediatric transplant, the MPSC proposes separate slightly lower pediatric boundaries for three of the four metrics. The MPSC asserts that this proposal improves upon the current performance evaluation system using reliable, available metrics that measure multiple aspects of transplant program patient care to create a better, more holistic transplant program performance monitoring system.

Additionally, the proposal includes a new section in Appendix M, *Review and Actions* that codifies the current peer review process. Other administrative changes have been made to Appendix M, *Review and Actions* to ensure consistency with the new peer visit section and Appendix N: *Definitions* to delete definitions for two defunct MPSC standing subcommittees and update the definition for the SRTR.

The Committee encourages all interested individuals to comment on this proposal in its entirety, but specifically asks for feedback on the following:
• Do you think transplant programs that fall within the performance improvement or “yellow” zone would take advantage of offered assistance and if so, what types of assistance would be most helpful?

• Would you support the future addition or replacement of the 1 year post-transplant graft survival with a longer-term period prevalent survival metric, such as 5-year period prevalent post-transplant graft survival?

• One of the desired attributes of a good monitoring system is the monitored entity understands the measures being used. In order to ensure this understanding:
  ▪ What types of resources do you anticipate needing to respond to these new metrics?
  ▪ Are you comfortable with the concept of risk adjustment or do you think additional education on risk adjustment is needed?
  ▪ What education resources do you need to describe these metrics to your patients?
Appendix D: Membership Requirements for Transplant Hospitals and Transplant Programs

D.13 Additional Transplant Program Requirements

A. Transplant Program Performance

The MPSC will conduct reviews of transplant program performance to identify potential risks to patient health or public safety, as evidenced by either:

1. The probability that the transplant program meets any of the following criteria is greater than 50% for adult transplants:

   a. The transplant program’s waitlist mortality rate ratio is greater than 1.75 during a 2 year period.
   b. The transplant program’s offer acceptance rate ratio is less than 0.30 during a 1 year period.
   c. The transplant program’s 90-day post-transplant graft survival hazard ratio is greater than 1.75 during a 2.5 year time period. For pancreas transplant programs, 90-day post-transplant patient survival hazard ratio is greater than 1.75 during a 2.5 year period.
   d. The transplant program’s 1-year post-transplant graft survival conditional on 90-day post-transplant graft survival hazard ratio is greater than 1.75 during a 2.5 year period.

2. The probability that the transplant program meets any of the following criteria is greater than 50% for pediatric transplants:

   a. The transplant program’s waitlist mortality rate ratio is greater than 1.75 during a 2 year period.
   b. The transplant program’s offer acceptance rate ratio is less than 0.35 during a 1 year period.
   c. The transplant program’s 90-day post-transplant graft survival hazard ratio is greater than 1.60 during a 2.5 year period.
   d. The transplant program’s 1-year post-transplant graft survival conditional on 90 day post-transplant graft survival hazard ratio is greater than 1.60 during a 2.5 year period.

If a transplant program meets either of the above criteria based on reports produced by Scientific Registry of Transplant Recipients (SRTR), it must participate in an MPSC performance review. As part of the transplant program review, the MPSC may require the member to take appropriate actions to determine if the program has demonstrated sustainable improvement.
including, but not limited to:

- Providing information about the program structure, procedures, protocols and quality review processes
- Adopting and implementing a plan for improvement
- Participating in an informal discussion with MPSC members as described in Appendix M: Reviews and Actions
- Participating in a peer visit as described in Appendix M: Reviews and Actions

Once a member is under transplant program performance review, the MPSC will continue to review the program until the MPSC determines that the program has made sufficient and sustainable improvements in acting to avoid risk to public health or patient safety.

If the MPSC’s review determines that a risk to patient health or public safety exists, the MPSC may request that a member inactivate or withdraw a designated transplant program, or a specific component of the program to mitigate the risk. Before the MPSC requests that a member inactivate or withdraw a designated transplant program or a specific component of the program due to concerns identified during a performance review, the MPSC must offer the member an informal discussion with the MPSC, as described in Appendix M: Reviews and Actions.

A member’s failure to fully participate in the review process or to act to avoid a risk to patient health or public safety may result in action taken under Appendix M: Reviews and Actions.

underperforming transplant programs and require the implementation of quality assessment and performance improvement measures. One measure of transplant program performance is triggered through a review of the one-year graft and patient survival rates. The MPSC utilizes performance metrics produced by the Scientific Registry of Transplant Recipients (SRTR) as the principal tool to identify transplant programs that have lower than expected outcomes.

For programs performing 10 or more transplants in a 2.5 year period, the MPSC will review a transplant program if it has a higher hazard ratio of mortality or graft failure than would be expected for that transplant program. The criteria used to identify programs with a hazard ratio that is higher than expected will include either of the following:

1. The probability is greater than 75% that the hazard ratio is greater than 1.2.
2. The probability is greater than 10% that the hazard ratio is greater than 2.5.

For programs performing 9 or fewer transplants in a 2.5 year period, the MPSC will review a transplant program if the program has one or more events in a 2.5 year cohort.

The MPSC review will be to determine if the higher hazard ratio or events can be explained by patient mix or some other unique clinical aspect of the transplant program. If a program’s performance cannot be explained by patient mix or some other unique clinical aspect of the transplant program, the program, in cooperation with the MPSC, will adopt and promptly implement a plan for quality improvement. The member’s failure to adopt and promptly implement a plan for quality improvement will be considered a noncompliance with OPTN Obligations and may result in an OPTN action according to Appendix M: Reviews and Actions.
As part of this process, the MPSC may conduct a peer visit to the program at the member’s expense. The MPSC may also require, at its discretion, that the member participate in an informal discussion. The informal discussion will be conducted according to Appendix M: Reviews and Actions.

The MPSC may recommend that a member inactivate a program, or a component of a program, or withdraw its designated transplant program status based on patient safety concerns arising from review of the program’s graft and patient survival. The MPSC must offer the member an informal discussion before recommending that the program inactivate or withdraw its designated transplant program status. A program’s failure to inactivate or withdraw its designated transplant program status when the MPSC recommends it do so will be considered a noncompliance with OPTN Obligations and may result in an OPTN action according to Appendix M: Reviews and Actions.

Appendix M: Reviews and Actions

M.3 Medical Peer Review

The OPTN will conduct all deliberations and take all actions according to applicable medical peer review laws. Consistent with applicable laws, all inquiries, peer visits, deliberations, recommendations, and actions during member reviews by the OPTN will be kept confidential. All proceedings and records within the scope of these OPTN quality review activities are confidential. Members of any OPTN Committee attending the meeting in which a peer review is conducted, serving as a peer reviewer, working for or on behalf of the OPTN, or providing information to the OPTN for peer review activities, are entitled to confidentiality.

The OPTN will keep all materials, information, and correspondences to and from members and directly related to the OPTN peer review process confidential to promote quality improvement and full disclosure by OPTN members. Materials, information, and correspondences created by or for the peer review body are considered “directly related.”

The OPTN will not disclose any materials provided to the OPTN by the member, except as required by law. Materials prepared by members independent of the OPTN medical peer review process may be shared by members in their discretion.

M.6 Peer Visits

A peer visit is an objective, on-site evaluation of a member by experienced transplant professionals. The MPSC or MPSC Chair may require a member under any MPSC review participate in a peer visit.

The MPSC Chair will appoint the peer visit panel. The peer visit panel will have access to all information available to the MPSC prior to the site visit. While on site, the peer visit panel will review records, interview staff and tour the facilities as desired. After the visit, the peer visit panel will prepare a report for the MPSC. The MPSC will review the report and determine the appropriate next steps.
A member’s refusal to participate in the peer visit in the time and format determined by the MPSC Chair, or a member’s refusal to provide requested information or to make available requested personnel, will be considered a potential noncompliance with OPTN Obligations.

**M.89 Informal Discussions**

An informal discussion is a direct conversation between a group of MPSC members and a member currently under MPSC review. Informal discussions are intended to provide the MPSC and member an opportunity to openly discuss the review and seek feedback. Informal discussions are information gathering activities that may lead to a more efficient and effective review than written correspondence and document reviews alone.

**B. MPSC Informal Discussion Requests**

The MPSC or MPSC Chair may offer members currently under review one or more informal discussions at any time. A transplant program is entitled to an informal discussion before the MPSC recommends that the program, or a component of the program, inactivate or withdraw its designated transplant program status due to functional inactivity or transplant program performance reviews according to Appendix D: Membership Requirements for Transplant Hospitals and Transplant Programs.

**M.1415 Costs and Expenses**

**B. Reasonable Costs and Expenses**

Reasonable costs and expenses resulting from enforcement of OPTN Obligations will be reimbursed by the member, including any of the following:

1. Conducting other than routine on-site reviews
2. Peer visits
3. Reviewing and monitoring corrective action plans or plans for quality improvement
4. Conducting due process proceedings
5. Monitoring and conducting evaluations of transplant programs with lower than expected survival rates as described in Section D.12.A: Transplant Program Performance of these Bylaws, including on-site visits and monitoring plans for quality improvement

**C. Advanced Deposit for Reimbursable Costs and Expenses**

The Executive Director may require that the member make and maintain a deposit with the OPTN in an amount equal to the currently projected costs and expenses of any of the following:

1. OPTN on-site reviews
2. OPTN peer on-site reviews peer visits
3. The interview
4. The hearing
Appendix N: Definitions

Performance Analysis and Improvement Subcommittee (PAIS)
A subcommittee of the Membership and Professional Standards Committee charged with reviewing analyzing how a member’s actual performance, including post-transplant survival rates and functional activity levels, compares with expected performance.

Policy-Compliance Subcommittee (PCSC)
A subcommittee of the Membership and Professional Standard Committee charged with reviewing a member’s compliance with OPTN rules and regulations.

Scientific Registry of Transplant Recipients (SRTR)
The organization responsible for providing statistical and other analytic support to the OPTN, that provides ongoing evaluation of clinical data about donors, transplant candidates, and recipients, as well as patient and graft survival rates. The SRTR also provides analytic support to HHS in a variety of areas including: policy formulation and evaluation, system performance metrics, economic analysis, and preparation of recurring and special reports to Congress. The SRTR contract is awarded by HRSA, who oversees and funds it.
Appendix A

Tables A-1 through A-8 below provide data about programs that would have been identified by the proposed metrics using the SRTR Spring 2020 PST data set. This data was examined by the MPSC to determine if the proposed metrics identify significant outliers that are likely in need of performance improvement assistance in order to avoid a potential risk to patient health and public safety.

Table A-1: Data for programs identified by proposed adult criteria for waitlist mortality

<table>
<thead>
<tr>
<th>Number</th>
<th>Organ</th>
<th>Person Years</th>
<th>Observed</th>
<th>Expected</th>
<th>WM Rate Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HR</td>
<td>24.01</td>
<td>8</td>
<td>1.79</td>
<td>2.64</td>
</tr>
<tr>
<td>2</td>
<td>HR</td>
<td>70.32</td>
<td>14</td>
<td>4.37</td>
<td>2.51</td>
</tr>
<tr>
<td>3</td>
<td>HR</td>
<td>10.17</td>
<td>5</td>
<td>0.97</td>
<td>2.35</td>
</tr>
<tr>
<td>4</td>
<td>LU</td>
<td>24.13</td>
<td>6</td>
<td>2.06</td>
<td>1.97</td>
</tr>
<tr>
<td>5</td>
<td>LU</td>
<td>29.66</td>
<td>11</td>
<td>4.65</td>
<td>1.95</td>
</tr>
<tr>
<td>6</td>
<td>LU</td>
<td>43.68</td>
<td>9</td>
<td>3.66</td>
<td>1.94</td>
</tr>
<tr>
<td>7</td>
<td>LU</td>
<td>90.23</td>
<td>17</td>
<td>8</td>
<td>1.9</td>
</tr>
<tr>
<td>8</td>
<td>LI</td>
<td>77.78</td>
<td>21</td>
<td>10.3</td>
<td>1.87</td>
</tr>
<tr>
<td>9</td>
<td>LI</td>
<td>78.61</td>
<td>18</td>
<td>8.75</td>
<td>1.86</td>
</tr>
<tr>
<td>10</td>
<td>LU</td>
<td>248.43</td>
<td>60</td>
<td>31.66</td>
<td>1.84</td>
</tr>
<tr>
<td>11</td>
<td>HR</td>
<td>89.24</td>
<td>13</td>
<td>6.16</td>
<td>1.84</td>
</tr>
<tr>
<td>12</td>
<td>HR</td>
<td>82.05</td>
<td>15</td>
<td>7.49</td>
<td>1.79</td>
</tr>
<tr>
<td>13</td>
<td>LI</td>
<td>101.65</td>
<td>31</td>
<td>16.48</td>
<td>1.79</td>
</tr>
</tbody>
</table>

Table A-2: Data for programs identified by proposed adult criteria for offer acceptance

<table>
<thead>
<tr>
<th>Number</th>
<th>Organ</th>
<th>Offers</th>
<th>Observed</th>
<th>Expected</th>
<th>OA Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>KI</td>
<td>12953</td>
<td>29</td>
<td>180.72</td>
<td>0.17</td>
</tr>
<tr>
<td>2</td>
<td>KI</td>
<td>4970</td>
<td>8</td>
<td>56.21</td>
<td>0.17</td>
</tr>
<tr>
<td>3</td>
<td>LI</td>
<td>1266</td>
<td>14</td>
<td>90.85</td>
<td>0.17</td>
</tr>
<tr>
<td>4</td>
<td>LU</td>
<td>1041</td>
<td>7</td>
<td>46.31</td>
<td>0.19</td>
</tr>
<tr>
<td>5</td>
<td>KI</td>
<td>1913</td>
<td>9</td>
<td>56.53</td>
<td>0.19</td>
</tr>
<tr>
<td>6</td>
<td>LI</td>
<td>1269</td>
<td>12</td>
<td>59.7</td>
<td>0.23</td>
</tr>
<tr>
<td>7</td>
<td>KI</td>
<td>68962</td>
<td>75</td>
<td>323.66</td>
<td>0.24</td>
</tr>
<tr>
<td>8</td>
<td>KI</td>
<td>3556</td>
<td>40</td>
<td>174.03</td>
<td>0.24</td>
</tr>
<tr>
<td>9</td>
<td>LI</td>
<td>26</td>
<td>0</td>
<td>5.83</td>
<td>0.26</td>
</tr>
<tr>
<td>10</td>
<td>LU</td>
<td>352</td>
<td>3</td>
<td>16.36</td>
<td>0.27</td>
</tr>
<tr>
<td>11</td>
<td>LI</td>
<td>1021</td>
<td>14</td>
<td>54.94</td>
<td>0.28</td>
</tr>
<tr>
<td>12</td>
<td>HR</td>
<td>1674</td>
<td>26</td>
<td>97.1</td>
<td>0.28</td>
</tr>
<tr>
<td>13</td>
<td>LI</td>
<td>349</td>
<td>10</td>
<td>39.12</td>
<td>0.29</td>
</tr>
<tr>
<td>14</td>
<td>KI</td>
<td>2825</td>
<td>1</td>
<td>6.96</td>
<td>0.33</td>
</tr>
</tbody>
</table>
### Table A-3: Data for programs identified by proposed adult criteria for 90-day graft survival

<table>
<thead>
<tr>
<th>Number</th>
<th>Organ</th>
<th>Transplants</th>
<th>Observed</th>
<th>Expected</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>KI</td>
<td>140</td>
<td>13</td>
<td>3.01</td>
<td>2.99</td>
</tr>
<tr>
<td>2</td>
<td>KI</td>
<td>120</td>
<td>12</td>
<td>3.6</td>
<td>2.5</td>
</tr>
<tr>
<td>3</td>
<td>LI</td>
<td>59</td>
<td>9</td>
<td>2.54</td>
<td>2.43</td>
</tr>
<tr>
<td>4</td>
<td>KI</td>
<td>53</td>
<td>5</td>
<td>0.95</td>
<td>2.37</td>
</tr>
<tr>
<td>5</td>
<td>KI</td>
<td>41</td>
<td>4</td>
<td>0.65</td>
<td>2.27</td>
</tr>
<tr>
<td>6</td>
<td>HR</td>
<td>53</td>
<td>8</td>
<td>2.44</td>
<td>2.25</td>
</tr>
<tr>
<td>7</td>
<td>KI</td>
<td>198</td>
<td>12</td>
<td>4.63</td>
<td>2.11</td>
</tr>
<tr>
<td>8</td>
<td>LU</td>
<td>21</td>
<td>4</td>
<td>0.9</td>
<td>2.07</td>
</tr>
<tr>
<td>9</td>
<td>KI</td>
<td>44</td>
<td>4</td>
<td>0.91</td>
<td>2.06</td>
</tr>
<tr>
<td>10</td>
<td>KI</td>
<td>101</td>
<td>6</td>
<td>1.97</td>
<td>2.01</td>
</tr>
<tr>
<td>11</td>
<td>KI</td>
<td>86</td>
<td>6</td>
<td>2.16</td>
<td>1.93</td>
</tr>
<tr>
<td>12</td>
<td>HR</td>
<td>11</td>
<td>3</td>
<td>0.62</td>
<td>1.91</td>
</tr>
<tr>
<td>13</td>
<td>KI</td>
<td>200</td>
<td>10</td>
<td>4.33</td>
<td>1.9</td>
</tr>
<tr>
<td>14</td>
<td>LI</td>
<td>62</td>
<td>7</td>
<td>2.82</td>
<td>1.87</td>
</tr>
<tr>
<td>15</td>
<td>HR</td>
<td>28</td>
<td>4</td>
<td>1.23</td>
<td>1.86</td>
</tr>
<tr>
<td>16</td>
<td>LU</td>
<td>94</td>
<td>9</td>
<td>4.01</td>
<td>1.83</td>
</tr>
<tr>
<td>17</td>
<td>LI</td>
<td>60</td>
<td>7</td>
<td>2.93</td>
<td>1.82</td>
</tr>
<tr>
<td>18</td>
<td>LI</td>
<td>127</td>
<td>13</td>
<td>6.3</td>
<td>1.81</td>
</tr>
<tr>
<td>19</td>
<td>KI</td>
<td>633</td>
<td>29</td>
<td>15.44</td>
<td>1.78</td>
</tr>
</tbody>
</table>

### Table A-4: Data for programs identified by proposed adult criteria for 1-year post-transplant graft survival conditional on 90-day post-transplant graft survival

<table>
<thead>
<tr>
<th>Number</th>
<th>Organ</th>
<th>Transplants</th>
<th>Observed</th>
<th>Expected</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>KI</td>
<td>75</td>
<td>6</td>
<td>1.12</td>
<td>2.56</td>
</tr>
<tr>
<td>2</td>
<td>KI</td>
<td>107</td>
<td>7</td>
<td>1.74</td>
<td>2.41</td>
</tr>
<tr>
<td>3</td>
<td>LI</td>
<td>192</td>
<td>15</td>
<td>5.37</td>
<td>2.31</td>
</tr>
<tr>
<td>4</td>
<td>HR</td>
<td>166</td>
<td>13</td>
<td>4.57</td>
<td>2.28</td>
</tr>
<tr>
<td>5</td>
<td>LU</td>
<td>23</td>
<td>5</td>
<td>1.17</td>
<td>2.21</td>
</tr>
<tr>
<td>6</td>
<td>LU</td>
<td>43</td>
<td>7</td>
<td>2.13</td>
<td>2.18</td>
</tr>
<tr>
<td>7</td>
<td>LU</td>
<td>70</td>
<td>9</td>
<td>3.15</td>
<td>2.14</td>
</tr>
<tr>
<td>8</td>
<td>KI</td>
<td>24</td>
<td>3</td>
<td>0.39</td>
<td>2.09</td>
</tr>
<tr>
<td>9</td>
<td>KI</td>
<td>142</td>
<td>7</td>
<td>2.44</td>
<td>2.03</td>
</tr>
<tr>
<td>10</td>
<td>KI</td>
<td>248</td>
<td>11</td>
<td>4.49</td>
<td>2</td>
</tr>
<tr>
<td>11</td>
<td>KI</td>
<td>86</td>
<td>5</td>
<td>1.63</td>
<td>1.93</td>
</tr>
<tr>
<td>12</td>
<td>HR</td>
<td>80</td>
<td>6</td>
<td>2.18</td>
<td>1.91</td>
</tr>
<tr>
<td>13</td>
<td>KI</td>
<td>200</td>
<td>8</td>
<td>3.23</td>
<td>1.91</td>
</tr>
<tr>
<td>14</td>
<td>HR</td>
<td>59</td>
<td>5</td>
<td>1.71</td>
<td>1.89</td>
</tr>
<tr>
<td>15</td>
<td>KI</td>
<td>506</td>
<td>19</td>
<td>9.4</td>
<td>1.84</td>
</tr>
<tr>
<td>16</td>
<td>KI</td>
<td>482</td>
<td>14</td>
<td>6.93</td>
<td>1.79</td>
</tr>
</tbody>
</table>
Table A-5: Data for programs identified by proposed pediatric criteria for waitlist mortality

<table>
<thead>
<tr>
<th>Number</th>
<th>Organ</th>
<th>Person Years</th>
<th>Observed</th>
<th>Expected</th>
<th>WM Rate Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HR</td>
<td>8.56</td>
<td>6</td>
<td>0.97</td>
<td>2.7</td>
</tr>
<tr>
<td>2</td>
<td>HR</td>
<td>9.03</td>
<td>4</td>
<td>0.38</td>
<td>2.52</td>
</tr>
<tr>
<td>3</td>
<td>HR</td>
<td>24.97</td>
<td>9</td>
<td>2.45</td>
<td>2.47</td>
</tr>
<tr>
<td>4</td>
<td>HR</td>
<td>2.74</td>
<td>3</td>
<td>0.17</td>
<td>2.3</td>
</tr>
<tr>
<td>5</td>
<td>LI</td>
<td>39.19</td>
<td>7</td>
<td>1.96</td>
<td>2.27</td>
</tr>
<tr>
<td>6</td>
<td>HR</td>
<td>24.99</td>
<td>6</td>
<td>1.65</td>
<td>2.19</td>
</tr>
<tr>
<td>7</td>
<td>HR</td>
<td>11.77</td>
<td>5</td>
<td>1.36</td>
<td>2.08</td>
</tr>
<tr>
<td>8</td>
<td>HR</td>
<td>12.85</td>
<td>5</td>
<td>1.42</td>
<td>2.05</td>
</tr>
<tr>
<td>9</td>
<td>HR</td>
<td>13.54</td>
<td>6</td>
<td>2.21</td>
<td>1.9</td>
</tr>
<tr>
<td>10</td>
<td>LI</td>
<td>77.19</td>
<td>9</td>
<td>3.92</td>
<td>1.86</td>
</tr>
<tr>
<td>11</td>
<td>KI</td>
<td>12.79</td>
<td>2</td>
<td>0.16</td>
<td>1.85</td>
</tr>
<tr>
<td>12</td>
<td>HR</td>
<td>23.82</td>
<td>5</td>
<td>1.91</td>
<td>1.79</td>
</tr>
<tr>
<td>13</td>
<td>LI</td>
<td>25.29</td>
<td>4</td>
<td>1.35</td>
<td>1.79</td>
</tr>
<tr>
<td>14</td>
<td>KI</td>
<td>62.86</td>
<td>3</td>
<td>0.8</td>
<td>1.78</td>
</tr>
<tr>
<td>15</td>
<td>HR</td>
<td>11.81</td>
<td>3</td>
<td>0.85</td>
<td>1.75</td>
</tr>
</tbody>
</table>

Table A-6: Data for programs identified by proposed pediatric criteria for offer acceptance

<table>
<thead>
<tr>
<th>Number</th>
<th>Organ</th>
<th>Offers</th>
<th>Observed</th>
<th>Expected</th>
<th>OA Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>KI</td>
<td>191</td>
<td>3</td>
<td>17.34</td>
<td>0.26</td>
</tr>
<tr>
<td>2</td>
<td>HR</td>
<td>621</td>
<td>18</td>
<td>60.03</td>
<td>0.32</td>
</tr>
<tr>
<td>3</td>
<td>LU</td>
<td>133</td>
<td>0</td>
<td>4.14</td>
<td>0.33</td>
</tr>
<tr>
<td>4</td>
<td>KI</td>
<td>134</td>
<td>2</td>
<td>10.11</td>
<td>0.33</td>
</tr>
<tr>
<td>5</td>
<td>HR</td>
<td>123</td>
<td>5</td>
<td>18.39</td>
<td>0.34</td>
</tr>
<tr>
<td>6</td>
<td>KI</td>
<td>41</td>
<td>0</td>
<td>3.25</td>
<td>0.38</td>
</tr>
</tbody>
</table>

Table A-7: Data for programs identified by proposed pediatric criteria for 90-day graft survival

<table>
<thead>
<tr>
<th>Number</th>
<th>Organ</th>
<th>Transplants</th>
<th>Observed</th>
<th>Expected</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>KI</td>
<td>16</td>
<td>3</td>
<td>0.16</td>
<td>2.31</td>
</tr>
<tr>
<td>2</td>
<td>LI</td>
<td>40</td>
<td>8</td>
<td>2.37</td>
<td>2.29</td>
</tr>
<tr>
<td>3</td>
<td>KI</td>
<td>55</td>
<td>3</td>
<td>0.56</td>
<td>1.95</td>
</tr>
<tr>
<td>4</td>
<td>HR</td>
<td>14</td>
<td>3</td>
<td>0.57</td>
<td>1.95</td>
</tr>
<tr>
<td>5</td>
<td>HR</td>
<td>17</td>
<td>3</td>
<td>0.67</td>
<td>1.87</td>
</tr>
<tr>
<td>6</td>
<td>HR</td>
<td>20</td>
<td>3</td>
<td>0.79</td>
<td>1.79</td>
</tr>
<tr>
<td>7</td>
<td>HR</td>
<td>9</td>
<td>2</td>
<td>0.27</td>
<td>1.76</td>
</tr>
<tr>
<td>8</td>
<td>LU</td>
<td>11</td>
<td>2</td>
<td>0.28</td>
<td>1.76</td>
</tr>
</tbody>
</table>
Table A-8: Data for programs identified by proposed adult criteria for 1-year post-transplant graft survival conditional on 90-day post-transplant graft survival

<table>
<thead>
<tr>
<th>Number</th>
<th>Organ</th>
<th>Transplants</th>
<th>Observed</th>
<th>Expected</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HR</td>
<td>18</td>
<td>3</td>
<td>0.52</td>
<td>1.98</td>
</tr>
<tr>
<td>2</td>
<td>LU</td>
<td>2</td>
<td>2</td>
<td>0.06</td>
<td>1.94</td>
</tr>
<tr>
<td>3</td>
<td>LI</td>
<td>2</td>
<td>2</td>
<td>0.09</td>
<td>1.91</td>
</tr>
<tr>
<td>4</td>
<td>KI</td>
<td>44</td>
<td>2</td>
<td>0.19</td>
<td>1.82</td>
</tr>
<tr>
<td>5</td>
<td>LI</td>
<td>58</td>
<td>3</td>
<td>0.86</td>
<td>1.75</td>
</tr>
</tbody>
</table>